Search the Newsreel

80,000 stock options go to Ivana Rubino at ProMIS Neurosciences (PMN), exercisable at $9.37.

ProMIS Neurosciences (PMN) has awarded its Chief Commercial Officer, Ivana Rubino, 80,000 common stock options with an exercise price of $9.37 per share, expiring on October 5, 2036. Twenty-five percent of the options vest immediately on October 5, 2026, with the remainder vesting monthly …

A 12-share gift leaves NewMarket (NEU) director James E. Rogers holding 3,885 shares directly.

NewMarket Corp (NEU) director James E. Rogers reported a bona fide gift disposition of 12 common shares on October 2, 2026, with a reported transaction price of $0.00 per share. After this transfer, Rogers directly holds 3,885 common shares. This transaction was filed as …

ProMIS Neurosciences appoints Ivana Rubino as chief commercial officer

ProMIS Neurosciences Inc. (NASDAQ:PMN) has appointed Ivana Rubino as Chief Commercial Officer. Rubino brings over 15 years of biopharmaceutical experience in neuroscience, with a focus on Alzheimer's disease, and will lead the commercial strategy for PMN310, the company's investigational antibody for Alzheimer's. The company …

Neuronetics stock gained 1.85 percent after Q2 revenue beat

Neuronetics (STIM) stock rose 1.85% after reporting Q2 2026 revenue of $41.57 million, surpassing estimates by 3.20%. The company also narrowed its adjusted loss to $0.05 per share. Analysts have reaffirmed "Buy" ratings with price targets significantly above the current trading price.

NewMarket Corp Q3FY26 Results: Earnings release set for Oct 28

NewMarket Corporation is scheduled to release its third-quarter 2026 earnings on October 28, 2026, after the close of business. A conference call and webcast will follow on October 29, 2026, at 3:00 pm ET to discuss the financial results. The company operates through subsidiaries …

NewMarket Corp (NYSE:NEU): A Quality Investing Case With High ROIC and Strong Cash Flow

NewMarket Corp (NYSE:NEU) is highlighted as a quality investing case due to its high return on invested capital (ROIC) and strong cash flow, aligning with a "Caviar Cruise" screening methodology for durable, cash-generative companies. While meeting several criteria like strong profitability and low debt, …

NeuroOne reports preliminary Q4 revenue of $3.8 million

NeuroOne Medical Technologies Corporation announced preliminary unaudited product revenue of approximately $3.8 million for its fourth fiscal quarter, ending September 30, 2026, marking a 38.4% increase year-over-year. The company expects total fiscal year 2026 revenue to be about $10.5 million, reaching the top of …

uniQure trial setback hits ClearPoint Neuro stock

Neueon Corporation narrows Q1FY27 standalone loss to ₹82.11 lakh

Neuphoria Therapeutics Inc. (NEUP) Stock Price, News, Quote & History

This article provides a real-time stock quote and essential company information for Neuphoria Therapeutics Inc. (NEUP) from Yahoo Finance. It displays the current stock price, recent performance, and offers links to more detailed financial data, news, and community insights. The stock closed at 3.4300 …

NewMarket Corporation Schedules Conference Call and Webcast to Review Third Quarter 2026 Results

RICHMOND, Va., October 05, 2026--(BUSINESS WIRE)--NewMarket Corporation (NYSE: NEU) announced today it expects to release third quarter 2026 earnings at the close of business on Wednesday, October 28, 2026. The earnings announcement will also be available on the Company's website at www.NewMarket.com the following …

At $2.32 a share, Alto Neuroscience (ANRO) CFO exercises options for 55,000 shares.

Alto Neuroscience's President and CFO, Nicholas Conrad Smith, exercised options for 55,000 common shares at $2.32 per share on October 2, 2026. This transaction increased his direct holdings to 79,060 common shares, while he still holds 57,405 options. The options had a vesting schedule …

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NeuroOne Medical reports preliminary Q4 2026 revenue of $3.8M

NeuroOne Medical Technologies (NASDAQ:NMTC) reported preliminary fiscal fourth-quarter 2026 product revenue of $3.8 million, a 38.4% year-over-year increase, and full-year revenue of $10.5 million, hitting the top of its guidance. The company also announced securing its largest purchase order ever, valued at $4.5 million, …

NeuroOne NMTC Expects $3.8 Million Fiscal Q4 Product Revenue

NeuroOne Medical Technologies Corporation (NMTC) announced preliminary, unaudited fiscal fourth-quarter 2026 product revenue of approximately $3.8 million, a 38.4% increase year-over-year. The company also secured a record $4.5 million product purchase order in September and reported preliminary fiscal 2026 revenue of about $10.5 million, …

NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order

NeuroOne Medical Technologies (NMTC) announced preliminary fiscal fourth-quarter 2026 product revenue of $3.8 million, a 38.4% increase year-over-year. The company also reported expected full-year product revenue of $10.5 million, up 15.6%, and secured a record $4.5 million purchase order in September 2026, with $1.0 …

NeuroScientific Biopharmaceuticals (ASX:NSB) Rises 5% as StemSmart Program Progresses

Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value Stock

Neurocrine names Roberts CMO. Neurocrine Biosciences stock sits 23.07 percent below its high

Neurocrine Biosciences has appointed Eiry W. Roberts, M.D., as its new chief medical officer, succeeding Sanjay Keswani. The company reported strong second-quarter 2026 revenues of USD 959 million, a 39.50 percent increase year-over-year, and raised its 2026 INGREZZA net sales guidance. Despite these positive …

Understanding Momentum Shifts in (CLPT)

The article analyzes Clearpoint Neuro, Inc. (CLPT), highlighting weak sentiment across all horizons and a potential short bias. It details a significant risk-reward short setup targeting 34.2% downside with minimal risk. The analysis also provides institutional trading strategies for different risk profiles, including position …

Neuronetics stock fell 2.70 percent as Q2 growth emerged

Neuronetics stock (STIM) closed down 2.70 percent at USD 2.16 on October 2, 2026, despite Q2 2026 revenue beating consensus by 3.20 percent. The company reported an adjusted loss of USD 0.05 per share, an improvement year-over-year. Analysts maintain a "Moderate Buy" consensus with …

NewMarket stock reports strong Q2 profit growth

Neurocrine Biosciences Shares Jump on Fresh Long-term CRENESSITY Data Catalyst

NULL

NeuroSense Therapeutics Ltd. (NRSN) Stock Price, News, Quote & History

NEU5143999 Bond Profile: Coupon and Redemption

This article provides a detailed profile of the NEU5143999 bond issued by NewMarket Corporation. It outlines key bond details such as issuer information, issue and maturity dates, face value, and minimum denomination. The profile also covers coupon payments, including the semi-annual 2.70% fixed rate, …

NMTC Q3 2026 Earnings: Wider-Than-Expected Loss Meets a 13.69% Stock Rally - Tangible Book Value

Neurocrine names Eiry W. Roberts CMO and Neurocrine Biosciences stock gains 1.74 percent

Neurocrine Biosciences has appointed Eiry W. Roberts as Chief Medical Officer, a role she previously held. This strategic move aims to bolster the company's late-stage programs, including INGREZZA and crinecerfont. The announcement follows strong Q2 2026 revenue of USD 959.0 million, a 39% increase …

Alto Neuroscience Insider Sold Shares Worth $3,567,247, According to a Recent SEC Filing

An insider at Alto Neuroscience recently sold shares totaling $3,567,247. This transaction was disclosed in a recent SEC filing. The sale indicates a significant divestment by a company insider.

Technical Reactions to NEU Trends in Macro Strategies

This article provides a technical analysis of Newmarket Corp (NYSE: NEU), highlighting strong sentiment across all time horizons supporting an overweight bias. It presents AI-generated institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis indicating support and …

(NBXG) Volatility Zones as Tactical Triggers

The article provides a detailed analysis of Neuberger Berman Next Generation Connectivity Fund Inc. (NASDAQ: NBXG), highlighting strong sentiment across all horizons and an exceptional 33.0:1 risk-reward setup. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored to different risk …

(NBIX) Movement as an Input in Quant Signal Sets

This article analyzes Neurocrine Biosciences Inc. (NASDAQ: NBIX) through quantitative research, highlighting positive near-term sentiment within a long-term strength context despite a mid-term weak bias. It identifies a significant 41.1:1 risk-reward setup, targeting an 11.9% gain against a 0.3% risk. The analysis also provides …

NeuroPace Inc (NPCE) Shares Fall 3.4% -- What GF Score of 75 Tel

NeuroPace Inc (NPCE) shares dropped 3.4% to $12.70, trading 0.9% above its GF Value, indicating slight overvaluation. The company has a GF Score of 75/100, showing strong growth potential (9/10) but weak financial strength and profitability (both 3/10). Insider selling of $0.4 million over …

Alto Neuroscience president and CFO Smith sells $3.57m in shares

Nicholas Conrad Smith, President and CFO of Alto Neuroscience (NASDAQ:ANRO), sold approximately $3.57 million in common stock while simultaneously acquiring shares worth $316,982 through exercising employee stock options. These transactions, executed under a 10b5-1 trading plan, occurred after ANRO shares surged significantly over the …